Danaher Co. (NYSE:DHR) Stock Position Reduced by TD Private Client Wealth LLC

TD Private Client Wealth LLC cut its stake in shares of Danaher Co. (NYSE:DHR) by 8.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 16,458 shares of the conglomerate’s stock after selling 1,488 shares during the period. TD Private Client Wealth LLC’s holdings in Danaher were worth $3,778,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DHR. Heck Capital Advisors LLC purchased a new position in Danaher during the fourth quarter valued at approximately $27,000. Decker Retirement Planning Inc. purchased a new position in Danaher during the fourth quarter valued at approximately $31,000. Golden State Wealth Management LLC purchased a new position in Danaher during the fourth quarter valued at approximately $31,000. Strategic Financial Concepts LLC bought a new stake in Danaher in the fourth quarter worth approximately $31,000. Finally, Pineridge Advisors LLC grew its position in Danaher by 63.3% in the fourth quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock worth $34,000 after acquiring an additional 57 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Price Performance

NYSE:DHR opened at $211.63 on Friday. The stock has a market cap of $151.26 billion, a P/E ratio of 40.08, a PEG ratio of 2.66 and a beta of 0.82. Danaher Co. has a one year low of $196.80 and a one year high of $281.70. The company has a fifty day moving average price of $217.46 and a 200 day moving average price of $238.86. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period last year, the firm posted $2.09 EPS. Analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.60%. The ex-dividend date is Friday, March 28th. This is a positive change from Danaher’s previous quarterly dividend of $0.27. Danaher’s payout ratio is 24.24%.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. The trade was a 21.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 10.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on DHR shares. Scotiabank started coverage on shares of Danaher in a research report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 target price for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $277.00 target price (down from $299.00) on shares of Danaher in a research report on Thursday, January 30th. Stifel Nicolaus raised shares of Danaher from a “hold” rating to a “buy” rating and set a $260.00 target price for the company in a research report on Friday, March 14th. Raymond James reissued a “market perform” rating on shares of Danaher in a research report on Monday, February 3rd. Finally, StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Five equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $278.24.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.